Domainex spoke with PharmaTelevision in December 2014 to explain:
- the collaboration with ZoBio and the combination of Domainex's CDH technology with ZoBio's state-of-the-art NMR capabilities
- Domainex's work on behalf of Auspherix
- Domainex's future investment round plans
- How Domainex operates a hybrid business model to generate revenues and reduce burn rate
- How Domainex plans to partner its TBK1/IKKe programme for the treatment of inflammatory diseases
Get the Flash Player to see this video.